manta around mid-year
follow posit filgotinib finch data suggest potenti best class safeti
profil rais probabl success drive
increas pt eagerli await outcom plan fda meet
glean greater visibl time us file pipelin updat includ novel
inhibitor start phase plan poc studi first
toledo compound uc
guidanc cash burn reiter jefe in-lin
filgotinib finch efficaci in-lin safeti reassur potenti differenti
efficaci data phase finch trial ra suggest filgotinib efficaci
similar key competitor upadacitinib recent roadshow manag
highlight total consist efficaci data togeth
potenti two dose clinician appreci chronic condit posit
filgotinib well fourth jaki market importantli compar efficaci
best class safeti avoid typic thrombot event associ
jaki class filgotinib could consid better risk benefit profil
jaki differenti safeti profil potenti key drive use
manta male safeti studi could rate-limit step
partner gilead request meet us fda discuss exist dataset
possibl file finch data result on-going phase ii
manta male safeti trial submit later clariti fda
path forward gilead updat time manta data requir
file galapago sponsor manta-ray studi expand upon
manta includ rheumat diseas permit broader age rang seek
enrol total patient across studi requir fda
assess sperm count
regulatori file europ japan expect respect
multi-blockbust potenti filgotinib
forecast ww peak sale ra crohn diseas
ulcer coliti cumul contribut indic
npv probabl success phase ii data sjgren
syndrom form lupu could support view broad commerci
potenti phase psoriat arthriti start potenti also
ankylos spondyl
phase isabela programm lung fibrosi ipf phase
ii system sclerosi forecast ww peak sale ipf
launch phase ii roccella pinta trial osteoarthr
ipf respect also progress phase data first toledo
compound expect
price pt
price pt
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
march
suffici fund oper forese futur
cash burn forecast exclud potenti upsid
orphan diseas ipf could
possibl updat us regulatori path filgotinib
phase ii filgotinib sjgren cutan lupu data
respect
filgotinib phase iib/iii select ulcer coliti data
potenti file
phase ii iguana data atop dermat
regulatori approv filgotinib ra
lead product filgotinib underpin much valuat
remain focu encourag
competit profil phase finch ra programm
phase ii fitzroy crohn trial partner gilead
maximis commerci potenti
numer pipelin programm could also
crystallis valu via possibl mileston exist
allianc new deal particular lung fibrosi ipf
osteoarthr
filgotinib npv plu
posit filgotinib data crohn ulcer coliti
posit phase ii iguana result atop
dermat could worth around
posit phase isabela result
potenti catalyst could boost npv deriv
price per share/ad increment
pharma deal allianc could provid upsid
regulatori delay manta safeti concern filgotinib
could remov around valuat
efficaci and/or safeti concern filgotinib phase
crohn ulcer coliti trial could remov
share valuat
setback delay could remov
efficaci safeti concern ipf could
remov least
setback could reduc npv deriv price target
per share/ad
pleas see import disclosur inform page report
financi summari market data
estim valuat
pleas see import disclosur inform page report
reiter buy boost price target
lead product filgotinib underpin major sum-of-the-part
valuat remain focu investor gilead licens global right decemb
provid partner maximis drug commerci potenti abbvi
elect opt-out favour prioritis jak inhibitor upadacitinib
encourag filgotinib competit profil base phase iib darwin
phase finch rheumatoid arthriti ra clinic data result phase
ii fitzroy trial also suggest drug effect inflammatori bowel diseas
ibd forecast global blockbust potenti larg compris ra
pivot programm lung fibrosi ipf underway could
signific commerci potenti phase ii phase
indic partner servier osteoarthr out-
licens atop dermat could also underappreci phase ii asset
view numer pipelin programm could also crystallis valu notabl
toledo programm via possibl mileston exist allianc new deal
potenti drive posit share price momentum
safeti profil filgotinib
select inhibitor filgotinib promis safe conveni oral treatment
rheumatoid arthriti ra encourag phase ii data crohn diseas cd suggest
drug could also potenti ibd perhap greater unmet medic need
albeit smaller elig patient popul multipl proof-of-concept studi
indic on-going compar current approv biolog agent tnf
 humira filgotinib administ oral target specif rapid
onset sustain respons potenti monotherapi use
sale forecast ra cd ulcer coliti
uc cumul contribut indic
valuat per share probabl success
news flow possibl updat us regulatori path ra around mid-year
includ potenti manta male safeti data time eu japan file
phase ii data sjogren syndrom cutan lupu erythematosu
manta could rate-limit step us file
recal fda allow use highest filgotinib dose us site
phase iib darwin trial basi regulatori concern male reproduct
system base rat/dog toxicolog studi thu fda allow inclus
mg/day dose finch programm import posit view
understand darwin trial confirm clinic meaning chang male
hormon level includ ex-u patient
manta could final lay safeti concern rest view note
differ fda divis approv phase divers studi cd phase iib/
select studi uc patient trial enrol us male elig
receiv higher dose fail least one prior biolog
understand fda recent allow expans inclus criteria manta
help acceler enrol meanwhil galapago lead
manta-ray studi evalu semen paramet patient
rheumat diseas ra psoriat arthriti ankylos spondyl non-radiograph
pleas see import disclosur inform page report
axial spondyloarthr permit broader age rang year versu
year manta result studi may pool aim total
patient across studi requir fda assess sperm count
whilst expect european japanes file us file timelin
depend fda discuss whether possibl file exist finch
dataset result manta trial submit later clariti
fda path forward gilead updat time manta data
requir file
forecast peak sale ra cd uc understand
gilead galapago aim pursu develop filgotinib indic
includ crohn sub-popul given extens programm includ
ww peak sale contribut reflect filgotinib potenti use indic
beyond ra ibd note humira first anti-tnf biolog approv
commerci success part due regulatori approv
numer indic current believ humira global sale
use indic ra ibd henc estim contribut
diseas filgotinib repres around peak
estim tier royalti sale galapago partner gilead
anticip profit-shar co-promot benelux galapago still
elig receiv mileston depend
achiev sale target respons fund spend
pleas see import disclosur inform page report
hike price
per share price base sum-of-the-part valuat compris
probability-adjust npv filgotinib ipf osteoarthr
atop dermat cf partnership togeth net
exhibit galapago sourc potenti upsid downsid risk
pleas see import disclosur inform page report
exhibit filgotinib global sale gilead partnership model
pleas see import disclosur inform page report
pleas see import disclosur inform page report
pleas see import disclosur inform page report
exhibit galapago profit loss model
pleas see import disclosur inform page report
pleas see import disclosur inform page report
